10 [2] K. Beardsley, E. D. Wish, D. B. Fitzelle, K. O’Grady, and A. M. Arria, “Distance traveled to outpatient drug treatment and client retention,” Journal of Substance Abuse Treatment, vol. 25, no. 4, pp. 279–285, 2003. [3] S. K. Schmitt, C. S. Phibbs, and J. D. Piette, “The inﬂuence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatment,” Addictive Behaviors, vol. 28, no. 6, pp. 1183–1192, 2003. [4] S. Magura and A. Rosenblum, “Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored,” Mount Sinai Journal of Medicine, vol. 68, no. 1, pp. 62–74, 2001. [5] D. D. Simpson, G. W. Joe, and B. S. Brown, “Treatment retention and follow-up outcomes in the drug abuse treatment outcome study (DATOS),” Psychology of Addictive Behaviors, vol. 11, no. 4, pp. 294–307, 1997. [6] A. Rosenblum, M. Parrino, S. H. Schnoll et al., “Prescription opioid abuse among enrollees into methadone maintenance treatment,” Drug and Alcohol Dependence, vol. 90, no. 1, pp. 64–71, 2007. [7] T. J. Cicero, J. A. Inciardi, and A. Mun˜oz, “Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004,” Journal of Pain, vol. 6, no. 10, pp. 662–672, 2005. [8] R. A. Rettig and A. Yarmolinsky, Federal Regulation of Methadone Treatment, National Academy Press, Washington, DC, USA, 1995. [9] A. Rosenblum, H. Joseph, C. Fong, S. Kipnis, C. Cleland, and R. K. Portenoy, “Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities,” Journal of the American Medical Association, vol. 289, no. 18, pp. 2370–2378, 2003. [10] M. A. Ilgen, J. A. Trafton, and K. Humphreys, “Response to methadone maintenance treatment of opiate dependent patients with and without signiﬁcant pain,” Drug and Alcohol Dependence, vol. 82, no. 3, pp. 187–193, 2006. [11] U.S. Census Bureau, Population Division, “Geographic Terms and Deﬁnitions,” April, 2011, http://www.census.gov/ popest/geographic/. [12] United States Department of Agriculture, Rural–urban contin- uums for 2003. Economic Research Service, USDA, April, 2011, http://www.ers.usda.gov/data/ RuralUrbanContinuumCodes. [13] C. E. McCulloch and S. R. Searle, Generalized, Linear, and Mixed Models, Wiley, New York, NY, USA, 2001. [14] J. C. Pinheiro, D. M. Bates, S. DebRoy, D. Sarkar, and the R Core Team, “nlme: Linear and Nonlinear Mixed Eﬀects Mod- els. R package version 3.1-92,” 2009, http://www.R-project.org. [15] J. C. Pinheiro and D. M. Bates, Mixed-Eﬀects Models in S and S-PLUS, Springer, New York, NY, USA, 2000. [16] R Development Core Team, “R: a language and environ- ment for statistical computing,” R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0, December, 2010, http://www.R-project.org. [17] Substance Abuse and Mental Health Services Administra- tion, “Medication-Assisted Treatment for Substance Use Disorders: Opioid Treatment Program Directory,” Center for Substance Abuse Treatment, Division of Pharmaco- logic Therapies, Rockville, MD, December, 2010, http://dpt2 .samhsa.gov/treatment/. [18] R. T. Furst, C. Herrmann, R. Leung, J. Galea, and K. Hunt, “Heroin diﬀusion in the mid-Hudson region of New York state,” Addiction, vol. 99, no. 4, pp. 431–441, 2004. Journal of Environmental and Public Health [19] J. R. Havens, C. B. Oser, C. G. Leukefeld et al., “Diﬀerences in prevalence of prescription opiate misuse among rural and urban probationers,” American Journal of Drug and Alcohol Abuse, vol. 33, no. 2, pp. 309–317, 2007. [20] J. R. Havens, R. Walker, and C. G. Leukefeld, “Prescription opioid use in the rural Appalachia: a community-based study,” Journal of Opioid Management, vol. 4, no. 2, pp. 63–71, 2008. [21] Substance Abuse and Mental Health Services Administration, “The N-SSATS Report: Overview of Opioid Treatment Pro- grams within the United States: 2008,” Oﬃce of Applied Stud- ies, Rockville, MD, December, 2010, http://oas.samhsa.gov/ 2k10/222/222USOTP2k10Web.pdf. [22] “Code of Federal Regulations. Federal Opioid Treatment Standards. Title 42: Public Health,” April, 2011, http://edocket .access.gpo.gov/cfr 2009/octqtr/pdf/42cfr8.12.pdf. [23] T. F. Borders and B. M. Booth, “Research on rural residence and access to drug abuse services: where are we and where do we go?” Journal of Rural Health, vol. 23, no. 1, pp. 79–83, 2007. [24] K. Rost, J. Fortney, E. Fischer, and J. Smith, “Use, quality, and outcomes of care for mental health: the rural perspective,” Medical Care Research and Review, vol. 59, no. 3, pp. 231–265, 2002. [25] I. Pearl and B. Sproule, “Methadone Maintenance Treatment: Recommendations for Enhancing Pharmacy Services,” Center for Addiction and Mental Health, Toronto, Canada, December, 2010 http://knowledgex.camh.net/policy health/ substance use/mmt enhancing pharmacy services/Documents/ mmt enhancing pharmacy services.pdf. [26] E. A. Salsitz, H. Joseph, B. Frank et al., “Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983-1998),” Mount Sinai Journal of Medicine, vol. 67, no. 5–6, pp. 388–397, 2000. [27] A. T. Forum, “New York State Introduces Bill on OTP Location Restrictions AT Forum News Notes and Updates, #139, March,” December, 2010, http://www.atforum.com/news- updates/201003.php#nyotp. [28] L. A. Marsch, “The eﬃcacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis,” Addiction, vol. 93, no. 4, pp. 515–532, 1998. [29] R. P. Mattick, C. Breen, J. Kimber, and M. Davoli, “Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence,” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD002209, 2009. [30] J. O. Jacobson, “Place and attrition from substance abuse treatment,” Journal of Drug Issues, vol. 34, no. 1, pp. 23–49, 2004.